Clinical Trial

Transurethral Periprostatectomy Treatment of Cancerous Prostate Tissue

Study acronym: PERI III
Completed
View on ClinicalTrials.gov →
Summary
This goal of this clinical trial is to determine if the Vanquish System can safely and effectively treat cancerous tissue in the prostate. Researchers will also determine the best treatment dose, monitor safety during and immediately after the procedure, and examine prostate tissue after surgical removal to confirm how well the treatment destroyed targeted tissue. Patients enrolled have been diagnosed with prostate cancer and will undergo treatment with the Vanquish System before their scheduled radical prostatectomy.
Trial Details
NCT Number NCT07561502
Lead Sponsor Francis Medical Inc.
Conditions Prostate Cancer
Enrollment 32 participants
Start Date 2022-11-14
Primary Completion 2023-08-11 (estimated)
Study Completion 2023-08-11 (estimated)
Updated on ClinicalTrials.gov 2026-05-01